Market Research Logo

Biosimulation Market Analysis By Product (Software, Services, In-house Services, Contract Services), By Application (Drug Development, Drug Discovery), By End-use (Pharmaceutical & Biotechnology Companies, CROs, Regulatory Authorities, Academic Research I

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
Chapter 3. Market Snapshot
Chapter 4. Market Variables, Trends & Scope
4.1. Market segmentation & scope
4.2. Market Driver Analysis
4.3. Market Restraint Analysis
4.4. Penetration & growth prospect mapping
4.5. Biosimulation - SWOT Analysis, By Factor (political & legal, economic and technological)
4.6. Industry Analysis - Porter's
Chapter 5. Market Categorization 1: Product Estimates & Trend Analysis
5.1. Biosimulation market: Product movement analysis
5.2. Software
5.2.1. Software Market Estimates and Forecasts, 2013 - 2024 (USD Million)
5.3. Services
5.3.1. Services Market Estimates and Forecasts, 2013 - 2024 (USD Million)
5.3.2. In-house Services
5.3.2.1. In-house Services Market Estimates and Forecasts, 2013 - 2024 (USD Million)
5.3.3. Contract Services
5.3.3.1. Contract Services Market Estimates and Forecasts, 2013 - 2024 (USD Million)
Chapter 6. Market Categorization 2: Application Estimates & Trend Analysis
6.1. Biosimulation market: Application movement analysis
6.2. Drug Development
6.2.1. Drug Development Market Estimates and Forecasts, 2013 - 2024 (USD Million)
6.3. Drug Discovery
6.3.1. Drug Discovery Market Estimates and Forecasts, 2013 - 2024 (USD Million)
6.4. Others
6.4.1. Others Market Estimates and Forecasts, 2013 - 2024 (USD Million)
Chapter 7. Market Categorization 3: End-use Estimates & Trend Analysis
7.1. Biosimulation market: Application movement analysis
7.2. Pharmaceutical & Biotechnology Companies
7.2.1. Pharmaceutical &Biotechnology Companies Market Estimates and Forecasts, 2013 - 2024 (USD Million)
7.3. CROs
7.3.1. CROs Market Estimates and Forecasts, 2013 - 2024 (USD Million)
7.4. Regulatory Authorities
7.4.1. Regulatory Authorities Market Estimates and Forecasts, 2013 - 2024 (USD Million)
7.5. Academic Research Institutions
7.5.1. Academic Research Institutions Market Estimates and Forecasts, 2013 - 2024 (USD Million)
Chapter 8. Market Categorization 3: Regional Estimates & Trend Analysis, By Type & Application
8.1. Biosimulation Market Share by Region, 2015 & 2024
8.2. North America
8.2.1. North America Market Estimates and Forecasts, By Product, 2013 - 2024 (USD Million)
8.2.1.1. U.S. Market Estimates and Forecasts
8.2.1.2. Canada Market Estimates and Forecasts
8.2.2. North America Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
8.2.2.1. U.S. Market Estimates and Forecasts
8.2.2.2. Canada Market Estimates and Forecasts
8.2.3. North America Market Estimates and Forecasts, By End-use, 2013 - 2024 (USD Million)
8.2.3.1. U.S. Market Estimates and Forecasts
8.2.3.2. Canada Market Estimates and Forecasts
8.3. Europe
8.3.1. Europe Market Estimates and Forecasts, By Product, 2013 - 2024 (USD Million)
8.3.1.1. UK Market Estimates and Forecasts
8.3.1.2. Germany Market Estimates and Forecasts
8.3.2. Europe Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
8.3.2.1. UK Market Estimates and Forecasts
8.3.2.2. Germany Market Estimates and Forecasts
8.3.3. Europe Market Estimates and Forecasts, By End-use, 2013 - 2024 (USD Million)
8.3.3.1. UK Market Estimates and Forecasts
8.3.3.2. Germany Market Estimates and Forecasts
8.4. Asia Pacific
8.4.1. Asia Pacific Market Estimates and Forecasts, By Product, 2013 - 2024 (USD Million)
8.4.1.1. Japan Market Estimates and Forecasts
8.4.1.2. China Market Estimates and Forecasts
8.4.1.3. India Market Estimates and Forecasts
8.4.2. Asia Pacific Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
8.4.2.1. Japan Market Estimates and Forecasts
8.4.2.2. China Market Estimates and Forecasts
8.4.2.3. India Market Estimates and Forecasts
8.4.3. Asia Pacific Market Estimates and Forecasts, By End-use, 2013 - 2024 (USD Million)
8.4.3.1. Japan Market Estimates and Forecasts
8.4.3.2. China Market Estimates and Forecasts
8.4.3.3. India Market Estimates and Forecasts
8.5. Latin America
8.5.1. Latin America Market Estimates and Forecasts, By Product, 2013 - 2024 (USD Million)
8.5.1.1. Brazil Market Estimates and Forecasts
8.5.1.2. Mexico Market Estimates and Forecasts
8.5.2. Latin America Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
8.5.2.1. Brazil Market Estimates and Forecasts
8.5.2.2. Mexico Market Estimates and Forecasts
8.5.3. Latin America Market Estimates and Forecasts, By End-use, 2013 - 2024 (USD Million)
8.5.3.1. Brazil Market Estimates and Forecasts
8.5.3.2. Mexico Market Estimates and Forecasts
8.6. MEA
8.6.1. MEA Market Estimates and Forecasts, By Product, 2013 - 2024 (USD Million)
8.6.1.1. South Africa Market Estimates and Forecasts
8.6.2. MEA Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
8.6.2.1. South Africa Market Estimates and Forecasts
8.6.3. MEA Market Estimates and Forecasts, By End-use, 2013 - 2024 (USD Million)
8.6.3.1. South Africa Market Estimates and Forecasts
Chapter 9. Competitive Landscape
9.1. Strategy framework
9.2. Market participation categorization
9.3. Company Profiles
9.3.1. Certara USA, Inc.
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Product Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Simulation Plus, Inc.
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Product Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Dassault Systems SA
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Product Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Schrodinger, Inc.
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Product Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Advanced Chemistry Development, Inc.
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Product Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Chemical Computing Group, Inc.
9.3.6.1. Company Overview
9.3.6.2. Financial Performance
9.3.6.3. Product Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Physiomics PLC
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Product Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Entelos, Inc.
9.3.8.1. Company Overview
9.3.8.2. Financial Performance
9.3.8.3. Product Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Rhenovia Pharma Ltd.
9.3.9.1. Company Overview
9.3.9.2. Financial Performance
9.3.9.3. Product Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. Genedata AG
9.3.10.1. Company Overview
9.3.10.2. Financial Performance
9.3.10.3. Product Benchmarking
9.3.10.4. Strategic Initiatives
9.3.11. Leadscope, Inc.
9.3.11.1. Company Overview
9.3.11.2. Financial Performance
9.3.11.3. Product Benchmarking
9.3.11.4. Strategic Initiatives
9.3.12. Evidera, Inc.
9.3.12.1. Company Overview
9.3.12.2. Financial Performance
9.3.12.3. Product Benchmarking
9.3.12.4. Strategic Initiatives
9.3.13. Insilico Biotechnology AG
9.3.13.1. Company Overview
9.3.13.2. Financial Performance
9.3.13.3. Product Benchmarking
9.3.13.4. Strategic Initiatives
9.3.14. LeadInvent Technologies Pvt. Ltd.
9.3.14.1. Company Overview
9.3.14.2. Financial Performance
9.3.14.3. Product Benchmarking
9.3.14.4. Strategic Initiatives
9.3.15. InhibOx Ltd.
9.3.15.1. Company Overview
9.3.15.2. Financial Performance
9.3.15.3. Product Benchmarking
9.3.15.4. Strategic Initiatives
List of Tables
TABLE 1 North America biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 2 North America biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 3 North America biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 4 North America biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 5 North America biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 6 U.S. biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 7 U.S. biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 8 U.S. biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 9 U.S. biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 10 U.S. biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 11 Canada biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 12 Canada biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 13 Canada biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 14 Canada biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 15 Canada biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 16 Europe biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 17 Europe biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 18 Europe biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 19 Europe biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 20 Europe biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 21 Germany biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 22 Germany biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 23 Germany biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 24 Germany biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 25 Germany biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 26 UK biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 27 UK biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 28 UK biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 29 UK biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 30 UK biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 31 Asia Pacific biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 32 Asia Pacific biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 33 Asia Pacific biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 34 Asia Pacific biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 35 Asia Pacific biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 36 Japan biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 37 Japan biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 38 Japan biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 39 Japan biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 40 Japan biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 41 China biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 42 China biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 43 China biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 44 China biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 45 China biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 46 India biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 47 India biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 48 India biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 49 India biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 50 India biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 51 Latin America biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 52 Latin America biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 53 Latin America biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 54 Latin America biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 55 Latin America biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 56 Brazil biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 57 Brazil biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 58 Brazil biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 59 Brazil biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 60 Brazil biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 61 Mexico biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 62 Mexico biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 63 Mexico biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 64 Mexico biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 65 Mexico biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 66 MEA biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 67 MEA biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 68 MEA biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 69 MEA biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 70 MEA biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 71 South Africa biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 72 South Africa biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 73 South Africa biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 74 South Africa biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 75 South Africa biosimulation market, by end-use, 2013 - 2024 (USD Million)
List of Figures
FIG. 1 Market summary
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Penetration & growth prospect mapping
FIG. 6 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 7 Porter’s Five Forces Analysis
FIG. 8 Biosimulation market product outlook key takeaways
FIG. 9 Biosimulation market: Product movement analysis
FIG. 10 Global software market, 2013 - 2024 (USD Million)
FIG. 11 Global services market, 2013 - 2024 (USD Million)
FIG. 12 Global in-house services market, 2013 - 2024 (USD Million)
FIG. 13 Global contract services market, 2013 - 2024 (USD Million)
FIG. 14 Biosimulation market application outlook: Key takeaways
FIG. 15 Biosimulation market: Application movement analysis
FIG. 16 Global drug development market, 2013 - 2024 (USD Million)
FIG. 17 Global drug discovery market, 2013 - 2024 (USD Million)
FIG. 18 Global others market, 2013 - 2024 (USD Million)
FIG. 19 Regional market place: Key takeaways
FIG. 20 Regional outlook, 2015 & 2024
FIG. 21 Global pharmaceutical & biotechnological companies market, 2013 - 2024 (USD Million)
FIG. 22 Global CROs market, 2013 - 2024 (USD Million)
FIG. 23 Global regulatory authorities market, 2013 - 2024 (USD Million)
FIG. 24 Global research institutes market, 2013 - 2024 (USD Million)
FIG. 25 Regional market place: Key takeaways
FIG. 26 Regional outlook, 2015 & 2024
FIG. 27 North America biosimulation market, 2013 - 2024 (USD Million)
FIG. 28 U.S. biosimulation market, 2013 - 2024 (USD Million)
FIG. 29 Canada biosimulation market, 2013 - 2024 (USD Million)
FIG. 30 Europe biosimulation market, 2013 - 2024 (USD Million)
FIG. 31 Germany biosimulation market, 2013 - 2024 (USD Million)
FIG. 32 UK biosimulation market, 2013 - 2024 (USD Million)
FIG. 33 Asia Pacific biosimulation market, 2013 - 2024 (USD Million)
FIG. 34 Japan biosimulation market, 2013 - 2024 (USD Million)
FIG. 35 China biosimulation market, 2013 - 2024 (USD Million)
FIG. 36 India biosimulation market, 2013 - 2024 (USD Million)
FIG. 37 Latin America biosimulation market, 2013 - 2024 (USD Million)
FIG. 38 Brazil biosimulation market, 2013 - 2024 (USD Million)
FIG. 39 Mexico biosimulation market, 2013 - 2024 (USD Million)
FIG. 40 MEA biosimulation market, 2013 - 2024 (USD Million)
FIG. 41 South Africa biosimulation market, 2013 - 2024 (USD Million)
FIG. 42 Strategy framework
FIG. 43 Participant categorization

Biosimulation Market Analysis By Product (Software, Services, In-house Services, Contract Services), By Application (Drug Development, Drug Discovery), By End-use (Pharmaceutical & Biotechnology Companies, CROs, Regulatory Authorities, Academic Research Institutions) And Segment Forecasts To 2024

The biosimulation market is expected to reach USD 3.77 billion by 2024, according to a new study by Grand View Research, Inc. The unprecedented global shift in the adoption of unhealthy lifestyles is resulting in the high prevalence of chronic diseases, such as cancer and diabetes, is expected to drive the biosimulation market during the forecast period. In addition, the rising geriatric population base highly susceptible to acquire the aforementioned chronic diseases result in enhanced demand for highly efficacious pharmacological drugs. This high requirement of efficacious drugs can be effectively met at a faster rate through the incorporation of the in silico approach, thus creating a high potential for biosimulation market growth opportunities in the future. Furthermore, increasing drug resistance, high drug failure rate, and availability of limited drugs to treat several diseasessuch as AIDS, pneumonia, tuberculosis, and others indicate the indisputable requirement for the incorporation of biosimulation in the drug discovery and development process. The widespread application of the in silico approach to developing efficacious drugs would generate drugs of greater potency in the market within a shorter span.

The increasing demand can be attributed primarily to the significant cost reduction in the clinical trials and drug development & discovery process. This is due to the fact that the in silico software can predict adverse reactions, toxicity, and efficacy of the drugsin the early stages of the drug development, thereby reducing the probability of drug failure at the later stages and consequentially, control the overall expenditure. These above-mentioned factors serve as key reasons responsiblefor the heightened market demand.

Further key findings from the study suggest:

The services segment is expected to exhibit growth at a significant CAGR of over 16.0% during the forecast period. This is a consequence of rising inclination of the big pharmaceutical companies to outsource their biosimulation process so as to reduce the overall cost incurred in research and development and divert its focus toward their core capabilities.

The drug discovery segment is anticipated to witness an exponential CAGR of over 15.0% in the application segment. Associated benefits of biosimulation in drug discovery are anticipated to fuel the demand over the forecast period. These benefits include the elimination of potential drug failures, predict unfavorable drug interactions, and anticipate potential risks.

In addition to these, certain other advantages include increased drug efficacy through the evaluation of optimal synergistic combinations, enable study of the mechanistic actions of drugs, and identification ofthe most suitable dosage forms, which render the drug discovery segment a profitable zone.

In 2015, the pharmaceutical and biotechnology companies held a substantial share of this vertical of over 58.0% in 2015. This can be attributed to the consistent efforts of these companies to develop better medication options at a faster and cheaper rate through in silico biology techniques.

Likewise, the academic research applications are presumed to witness constant growth as a consequence of the presence of various academic research groups that are involved in the study of complex biological systems using computer models, such as by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

In 2015, North America dominated the overall biosimulation marketat over 50.0%. The presence of regulatory authorities, consistently inclined towards ensuring patient safety, is a crucial factor presumed to be responsible for the dominant market share ofthis region. Moreover, the presence of highly skilled professionals also serves as a significant growth driver.

The numerous collaborations amongst the leading playersthat are being undertaken to promote the incorporation of biosimulation systems are expected to be responsible for bolstering the growth inthis region. For instance, Entelos, Inc. collaborated with Bayer AG to develop novel gene-based drug targets and also with Johnson & Johnson, Inc. to optimize clinical trial designs through in silico models.

Some of the leading players in this industry include Certara USA, Inc., Simulation Plus, Inc., Dassault Systems SA, Rhenovia Pharma Ltd., and Evidera, Inc. These players are actively involved in initiating collaborative strategies and frequent product launches to capture a larger share of the vertical.For instance, In April 2016, Simulation Plus, Inc. launched the DDDPlus Version 5.0, invitro dissolution experiment software. This upgraded version includes improvements in functionalities of the software that enable scientists and researchers to study the behavior of different pharmaceutical dosage forms.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;